|
|
|
Lupus Clinical Trials |
|
Thank you for your interest in clinical trials for Lupus
Please click "Search" to find Lupus clinical trials and medical research studies.
If you receive too many study listings you may enter your zip code to find the locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 2 studies:
|
|
|
|
|
Results from other databases:
|
|
|
|
Your search returned 193 studies:
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-06030
Conditions: Lupus
Location: Farmington, CT
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-16635
Conditions: Lupus
Location: Duncansville, PA
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-21205
Conditions: Lupus
Location: Baltimore, MD
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-27834
Conditions: Lupus
Location: Greenville, NC
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-28210
Conditions: Lupus
Location: Charlotte, NC
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-29406
Conditions: Lupus
Location: North Charleston, SC
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-30033
Conditions: Lupus
Location: Decatur, GA
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-30060
Conditions: Lupus
Location: Marietta, GA
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-30303
Conditions: Lupus
Location: Atlanta, GA
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-33765
Conditions: Lupus
Location: Clearwater, FL
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-34474
Conditions: Lupus
Location: Ocala, FL
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-36207
Conditions: Lupus
Location: Anniston, AL
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-45219
Conditions: Lupus
Location: Cincinnati, OH
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-48910
Conditions: Lupus
Location: Lansing, MI
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-73104
Conditions: Lupus
Location: Oklahoma City, OK
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-77479
Conditions: Lupus
Location: Sugarland, TX
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-80910
Conditions: Lupus
Location: Colorado Springs, CO
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus - NCT00657189-92646
Conditions: Lupus
Location: Huntington Beach, CA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-11042
Conditions: Systemic Lupus Erythematosus
Location: Lake Sucess, NY
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-11576
Conditions: Systemic Lupus Erythematosus
Location: Roslyn, NY
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-15213
Conditions: Systemic Lupus Erythematosus
Location: Pittsburgh, PA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-18015
Conditions: Systemic Lupus Erythematosus
Location: Bethlehem, PA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-18166
Conditions: Systemic Lupus Erythematosus
Location: Allentown, PA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-19141
Conditions: Systemic Lupus Erythematosus
Location: Philadelphia, PA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-21502
Conditions: Systemic Lupus Erythematosus
Location: Cumberland, MD
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-21740
Conditions: Systemic Lupus Erythematosus
Location: Hagerstown, MD
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-27834
Conditions: Systemic Lupus Erythematosus
Location: Greenville, NC
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-28210
Conditions: Systemic Lupus Erythematosus
Location: Charlotte, NC
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-29406
Conditions: Systemic Lupus Erythematosus
Location: Charleston, SC
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-32806
Conditions: Systemic Lupus Erythematosus
Location: Orlando, FL
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-33180
Conditions: Systemic Lupus Erythematosus
Location: Aventura, FL
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-33765
Conditions: Systemic Lupus Erythematosus
Location: Clearwater, FL
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-35294
Conditions: Systemic Lupus Erythematosus
Location: Birmingham, AL
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-36207
Conditions: Systemic Lupus Erythematosus
Location: Anniston, AL
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-74104
Conditions: Systemic Lupus Erythematosus
Location: Tulsa, OK
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-77004
Conditions: Systemic Lupus Erythematosus
Location: Houston, TX
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-77034
Conditions: Systemic Lupus Erythematosus
Location: Houston, TX
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-77479
Conditions: Systemic Lupus Erythematosus
Location: Sugar Land, TX
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-83814
Conditions: Systemic Lupus Erythematosus
Location: Coeur D'Alene, ID
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-85724
Conditions: Systemic Lupus Erythematosus
Location: Tucson, AZ
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-90048
Conditions: Systemic Lupus Erythematosus
Location: Los Angeles, CA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-90806
Conditions: Systemic Lupus Erythematosus
Location: Long Beach, CA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-91786
Conditions: Systemic Lupus Erythematosus
Location: Upland, CA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-94578
Conditions: Systemic Lupus Erythematosus
Location: San Leandro, CA
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus - NCT00962832-99204
Conditions: Systemic Lupus Erythematosus
Location: Spokane, WA
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-02115
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Boston, MA
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-10003
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: NY, NY
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-10032
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: New York, NY
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-11030
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Manhasset, NY
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-14642
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Rochester, NY
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-15261
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Pittsburgh, PA
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-19147
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Philadelphia, PA
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-27599
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Chapel Hill, NC
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-33136
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Miami, FL
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-35294
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Birmingham, AL
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-43210
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Columbus, OH
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-48109
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Ann Arbor, MI
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-48201
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Detroit, MI
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-60637
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Chicago, IL
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-73104
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Oklahoma City, OK
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-75390
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Dallas, TX
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-90048
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: Los Angeles, CA
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-92037
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: La Jolla, CA
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-94143
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Location: San Francisco, CA
- Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus - NCT00325741-94305
Conditions: Lupus Erythematosus, Systemic
Location: Stanford, CA
- Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus - NCT00278590-60611
Conditions: Systemic Lupus Erythematosus
Location: Chicago, IL
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-10021
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: New York, NY
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-11030
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Manhasset, NY
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-11042
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Lake Success, NY
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-16635
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Duncansville, PA
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-27710
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Durham, NC
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-29425
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Charleston, SC
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-30303
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Atlanta, GA
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-35294
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Birmingham, AL
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-66160
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Kansas City, KS
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-75390
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Dallas, TX
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-90024
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Los Angeles, CA
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-90048
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Los Angeles, CA
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-92037
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: La Jolla, CA
- An Investigation of of NNC 0152-0000-0001 in Patients With Systemic Lupus Erythematosus (SLE) - NCT00960362-94304
Conditions: Inflammation - Systemic Lupus Erythematosus (SLE)
Location: Palo Alto, CA
- Aspirin Resistance in Systemic Lupus Erythematosus (SLE) - NCT00731302-02215
Conditions: Systemic Lupus Erythematosus
Location: Boston, MA
- Aspirin Resistance in Systemic Lupus Erythematosus (SLE) - NCT00731302-37232
Conditions: Systemic Lupus Erythematosus
Location: Nashville, TN
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-
Conditions: Systemic Lupus Erythematosus, SLE
Location: Seattle, WA
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-02115
Conditions: Systemic Lupus Erythematosus, SLE
Location: Boston, MA
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-02370
Conditions: Systemic Lupus Erythematosus, SLE
Location: Rockland, MA
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-10021
Conditions: Systemic Lupus Erythematosus, SLE
Location: New York, NY
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-11030
Conditions: Systemic Lupus Erythematosus, SLE
Location: Manhasset, NY
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-35249
Conditions: Systemic Lupus Erythematosus, SLE
Location: Birmingham, AL
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-48201
Conditions: Systemic Lupus Erythematosus, SLE
Location: Detroit, MI
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-48910
Conditions: Systemic Lupus Erythematosus, SLE
Location: Lansing, MI
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-60611
Conditions: Systemic Lupus Erythematosus, SLE
Location: Chicago, IL
- Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus - NCT00624338-85259
Conditions: Systemic Lupus Erythematosus, SLE
Location: Scottsdale, AZ
- Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus - NCT00412841-10003
Conditions: Avascular Necrosis
Location: New York, NY
- Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis - NCT00594932-73104
Conditions: Systemic Lupus Erythematosus - Arthritis
Location: Oklahoma City, OK
- Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) - NCT00987831-73104
Conditions: Systemic Lupus Erythematosus
Location: Oklahoma City, OK
- Cardiology Prevention in Systemic Lupus Erythematosus (SLE) - NCT00610805-15213
Conditions: Systemic Lupus Erythematosus
Location: Pittsburgh, PA
- Cardiology Prevention in Systemic Lupus Erythematosus (SLE) - NCT00610805-15261
Conditions: Systemic Lupus Erythematosus
Location: Pittsburgh, PA
- Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus - NCT00582881-33101
Conditions: Mixed Connective Tissue Disease - Systemic Lupus Erythematosus
Location: Miami, FL
- CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study - NCT00522002-20007
Conditions: Connective Tissue Diseases - Blood Coagulation Disorders - Leg Ulcers - Rheumatoid Arthritis - Systemic Lupus Erythematosus - Systemic Scleroderma - Mixed Connective Tissue Disease
Location: Washington, DC
- Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus - NCT00278538-60611A
Conditions: Systemic Lupus Erythematosus
Location: Chicago, IL
- Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus - NCT00278538-60611B
Conditions: Systemic Lupus Erythematosus
Location: Chicago, IL
- Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention - NCT00189124-48109
Conditions: Systemic Lupus Erythematosus
Location: Ann Arbor, MI
- Doxycycline Outcomes in Lupus Erythematosus: (DOLE) - NCT01014260-21205
Conditions: Cardiovascular Disease
Location: Baltimore, MD
- Duke Autoimmunity in Pregnancy Registry - NCT00513591-27710
Conditions: Pregnancy - Systemic Lupus Erythematosus - Cutaneous Lupus - Rheumatoid Arthritis - Sjogren's Syndrome - Scleroderma
Location: Durham, NC
- Duke Lupus Registry - NCT00512694-27710
Conditions: Systemic Lupus Erythematosus - Cutaneous Lupus
Location: Durham, NC
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-02118
Conditions: Systemic Lupus Erythematosus
Location: Boston, MA
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-10021
Conditions: Systemic Lupus Erythematosus
Location: New York, NY
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-11030
Conditions: Systemic Lupus Erythematosus
Location: Manhasset, NY
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-11042
Conditions: Systemic Lupus Erythematosus
Location: Lake Success, NY
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-11203
Conditions: Systemic Lupus Erythematosus
Location: Brooklyn, NY
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-13210
Conditions: Systemic Lupus Erythematosus
Location: Syracuse, NY
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-27599
Conditions: Systemic Lupus Erythematosus
Location: Chapel Hill, NC
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-30342
Conditions: Systemic Lupus Erythematosus
Location: Atlanta, GA
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-35294
Conditions: Systemic Lupus Erythematosus
Location: Birmingham, AL
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-37909
Conditions: Systemic Lupus Erythematosus
Location: Knoxville, TN
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-55415
Conditions: Systemic Lupus Erythematosus
Location: Minneapolis, MN
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-66160
Conditions: Systemic Lupus Erythematosus
Location: Kansas City, KS
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-73104
Conditions: Systemic Lupus Erythematosus
Location: Oklahoma City, OK
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-77004
Conditions: Systemic Lupus Erythematosus
Location: Houston, TX
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-80218
Conditions: Systemic Lupus Erythematosus
Location: Denver, CO
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-85724
Conditions: Systemic Lupus Erythematosus
Location: Tucson, AZ
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-90048
Conditions: Systemic Lupus Erythematosus
Location: Los Angeles, CA
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-90095
Conditions: Systemic Lupus Erythematosus
Location: Los Angeles, CA
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-90806
Conditions: Systemic Lupus Erythematosus
Location: Long Beach, CA
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis - NCT00430677-98101
Conditions: Systemic Lupus Erythematosus
Location: Seattle, WA
- Efficacy of Fish Oil in Lupus Patients - NCT00828178-21205
Conditions: Systemic Lupus Erythematosus
Location: Baltimore, MD
- Estrogen and Gender Biased Autoimmunity - NCT00519454-64111
Conditions: Systemic Lupus Erythematosus
Location: Kansas City, MO
- Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) - NCT00633945-19104
Conditions: Cutaneous Lupus Erythematosus (CLE)
Location: Philadelphia, PA
- Genetic Study of Lupus Patients and Their Families - NCT00235378-55455
Conditions: Systemic Lupus Erythematosus
Location: Minneapolis, MN
- Health-related Quality of Life Measure in Pediatric Lupus - NCT00280137-07039
Conditions: Systemic Lupus Erythematosus - Quality of Life
Location: Livingston, NJ
- Health-related Quality of Life Measure in Pediatric Lupus - NCT00280137-08903
Conditions: Systemic Lupus Erythematosus - Quality of Life
Location: New Brunswick, NJ
- Health-related Quality of Life Measure in Pediatric Lupus - NCT00280137-10021
Conditions: Systemic Lupus Erythematosus - Quality of Life
Location: New York, NY
- Health-related Quality of Life Measure in Pediatric Lupus - NCT00280137-44106
Conditions: Systemic Lupus Erythematosus - Quality of Life
Location: Cleveland, OH
- Health-related Quality of Life Measure in Pediatric Lupus - NCT00280137-44195
Conditions: Systemic Lupus Erythematosus - Quality of Life
Location: Cleveland, OH
- Health-related Quality of Life Measure in Pediatric Lupus - NCT00280137-60615
Conditions: Systemic Lupus Erythematosus - Quality of Life
Location: Chicago, IL
- Immune System Related Kidney Disease - NCT00001979-20892
Conditions: Glomerulonephritis - Lupus Nephritis - Membranous Glomerulonephritis - Nephritis - Nephrotic Syndrome
Location: Bethesda, MD
- Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women - NCT00786409-60637
Conditions: Systemic Lupus Erythematosus
Location: Chicago, IL
- Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies - NCT00581763-94143
Conditions: Lupus
Location: San Francisco, CA
- Lupus Genetics Studies - NCT00071175-73104
Conditions: Systemic Lupus Erythematosus
Location: Oklahoma City, OK
- Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus - NCT00730002-48109
Conditions: Neuropsychiatric Systemic Lupus Erythematosus
Location: Ann Arbor, MI
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-07601
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Hackensack, NJ
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-10032
Conditions: Systemic Lupus Erythematosus - Lupus
Location: New York, NY
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-43205
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Columbus, OH
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-45229
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Cincinnati, OH
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-53226
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Milwaukee, WI
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-60614
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Chicago, IL
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-73104
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Oklahoma City, OK
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-90027
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Los Angeles, CA
- New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus - NCT00088244-98105
Conditions: Systemic Lupus Erythematosus - Lupus
Location: Seattle, WA
- Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases - NCT00849745-27705
Conditions: Multiple Sclerosis - Systemic Lupus Erythematosus
Location: Durham, NC
- Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis - NCT00908986-11030
Conditions: Lupus Nephritis
Location: Manhasset, NY
- Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-Thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders - NCT00010335-98109
Conditions: Systemic Sclerosis - Systemic Lupus Erythematosus - Dermatomyositis - Juvenile Rheumatoid Arthritis - Autoimmune Diseases
Location: Seattle, WA
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-02905
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: Providence, RI
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-10016
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: New York, NY
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-10021
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: New York, NY
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-10032
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: New York, NY
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-21287
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: Baltimore, MD
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-60637
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: Chicago, IL
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-73104
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: Oklahoma City, OK
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) - NCT00198068-84132
Conditions: Systemic Lupus Erythematosus - Antiphospholipid Syndrome
Location: Salt Lake City, UT
- Prospective Study of Rapamycin for the Treatment of SLE - NCT00779194-13210
Conditions: Systemic Lupus Erythematosus (SLE)
Location: Syracuse, NY
- Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis - NCT00818948-
Conditions: Lupus - Nephritis - Systemic Lupus Erythematosus
Location: Amarillo, TX
- Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients - NCT00708916-10016
Conditions: Discoid Lupus Erythematosus
Location: New York City, NY
- Sirolimus for Autoimmune Disease of Blood Cells - NCT00392951-19104
Conditions: Autoimmune Cytopenias - Autoimmune Lymphoproliferative Syndrome (ALPS) - Evans Syndrome - Idiopathic Thrombocytopenic Purpura - Anemia, Hemolytic, Autoimmune - Autoimmune Neutropenia - Lupus - Inflammatory Bowel Disease - Rheumatoid Arthritis
Location: Philadelphia, PA
- Study Evaluating the SBI-087 in Subjects With Systemic Lupus Erythematosus - NCT00714116-16635
Conditions: Lupus Erythematosus, Systemic
Location: Duncansville, PA
- Study Evaluating the SBI-087 in Subjects With Systemic Lupus Erythematosus - NCT00714116-27710
Conditions: Lupus Erythematosus, Systemic
Location: Durham, NC
- Study Evaluating the SBI-087 in Subjects With Systemic Lupus Erythematosus - NCT00714116-33143
Conditions: Lupus Erythematosus, Systemic
Location: Miami, FL
- Study Evaluating the SBI-087 in Subjects With Systemic Lupus Erythematosus - NCT00714116-75235
Conditions: Lupus Erythematosus, Systemic
Location: Dallas, TX
- Systemic Lupus Erythematosus in Gullah Health - NCT00756769-
Conditions: Systemic Lupus Erythematosus
Location: Augusta, GA
- Systemic Lupus Erythematosus in Gullah Health - NCT00756769-29425
Conditions: Systemic Lupus Erythematosus
Location: Charleston, SC
- The Research Registry for Neonatal Lupus - NCT00074373-10016
Conditions: Neonatal Lupus - Systemic Lupus Erythematosus - Sjogren's Syndrome - Congenital Heart Block
Location: New York, NY
- The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus - NCT00797784-33136
Conditions: Discoid Lupus Erythematosus (DLE)
Location: Miami, FL
- Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser - NCT00523588-19104
Conditions: Cutaneous Lupus Erythematosus
Location: Philadelphia, PA
- Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine - NCT00775476-13210
Conditions: Systemic Lupus Erythematosus
Location: Syracuse, NY
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-07601
Conditions: Systemic Lupus Erythematosus
Location: Hackensack, NJ
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-10032
Conditions: Systemic Lupus Erythematosus
Location: New York, NY
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-43205
Conditions: Systemic Lupus Erythematosus
Location: Columbus, OH
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-45229
Conditions: Systemic Lupus Erythematosus
Location: Cincinnati, OH
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-53226
Conditions: Systemic Lupus Erythematosus
Location: Milwaukee, WI
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-60614
Conditions: Systemic Lupus Erythematosus
Location: Chicago, IL
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-73104
Conditions: Systemic Lupus Erythematosus
Location: Oklahoma City, OK
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-90027
Conditions: Systemic Lupus Erythematosus
Location: Los Angeles, CA
- Triptorelin for Ovary Protection in Childhood Onset Lupus - NCT00124514-98105
Conditions: Systemic Lupus Erythematosus
Location: Seattle, WA
- Ultraviolet Light Therapy for Systemic Lupus Erythematosus - NCT00004375-70112
Conditions: Systemic Lupus Erythematosus
Location: New Orleans, LA
- Ultraviolet Light Therapy for Systemic Lupus Erythematosus - NCT00004375-70121
Conditions: Systemic Lupus Erythematosus
Location: New Orleans, LA
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-
Conditions: Systemic Lupus Erythematosus
Location: Pittsburgh, PA
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-02115
Conditions: Systemic Lupus Erythematosus
Location: Boston, MA
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-11030
Conditions: Systemic Lupus Erythematosus
Location: Manhassett, NY
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-14642
Conditions: Systemic Lupus Erythematosus
Location: Rochester, NY
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-27710
Conditions: Systemic Lupus Erythematosus
Location: Durham, NC
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-29425
Conditions: Systemic Lupus Erythematosus
Location: Charleston, SC
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-35294
Conditions: Systemic Lupus Erythematosus
Location: Birmingham, AL
- Vitamin D3 in Systemic Lupus Erythematosus - NCT00710021-94143
Conditions: Systemic Lupus Erythematosus
Location: San Francisco, CA
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|